CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
stockholders elected the directors of the Company named below to
serve until the next annual meeting of stockholders or until
their respective successors are elected and qualified.
Stockholders also ratified the selection of BDO USA LLP as the
Company’s independent registered certified accountants to audit
the Company’s financial statements as of and for the year ending
December 31, 2017, and approved, on an advisory basis, the
compensation paid to the Company’s named executive officers. A
tabulation of the matters voted on at this annual stockholder
meeting is set forth below.
|
Proposal #1: Election of Directors
|
Kathy L. Davis
|
Peter Kissinger
|
Dr. Gary Meller
|
John J. Sperzel III
|
||||
|
For
|
5,356,287
|
5,356,338
|
5,354,456
|
5,779.281
|
||||
|
Withheld/Against
|
574,328
|
574,277
|
576,159
|
151,334
|
||||
|
Broker non-votes
|
4,617,503
|
4,617,503
|
4,617,503
|
4,617,503
|
| Proposal #2 | Proposal #3 | |||
|
Ratifying BDO USA LLP as the Company’s Independent
Auditors for the year ending December 31, 2017 |
Approve Compensation paid to the Company’s named Executive
Officers |
|||
|
For
|
10,524,627
|
5,669,227
|
||
|
Withheld/Against
|
13,548
|
152,402
|
||
|
Abstain
|
9,943
|
108,986
|
||
|
Broker non-votes
|
—
|
4,617,503
|
Adjourn or Postpone the Meeting.
About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)
Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies. CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Recent Trading Information
CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) closed its last trading session down -0.05 at 6.75 with 10,510 shares trading hands.